According
to the National Cancer Institute the overall survival rate at 6 years
for patients with colon cancer stage III who received FOLFOX (oxaliplatin,
leucovorin and fluorouracil [5-FU]) was 72.9% and 68.9% for patients
receiving 5-FU/LV (5-FU and levamisole).

According
to the American Cancer Society, the 5-year survival rate for colon
cancer stage 3b is a 64 percent.